Merrimack Pharmaceuticals Inc (NASDAQ:MACK), Director Michael E. Porter acquired 15,000 shares of Merrimack Pharmaceuticals stock in a transaction dated Monday, May 5th. The shares were purchased at an average cost of $6.41 per share, for a total transaction of $96,150.00. Following the purchase, the director now directly owns 485,865 shares in the company, valued at approximately $3,114,395. Merrimack Pharmaceuticals Inc (NASDAQ:MACK), shares after opening at $6.31 moved to $7.07 on last trade day and at the end of the day closed at $6.87. Company price to sales ratio in past twelve months was calculated as 15.35 and price to cash ratio as 4.57. Merrimack Pharmaceuticals Inc (NASDAQ:MACK), showed a positive weekly performance of 54.73%.
HCA Holdings Inc (NYSE:HCA), Director John Rowe bought 14,356 shares of HCA Holdings stock on the open market in a transaction that occurred on Wednesday, April 30th. The stock was purchased at an average price of $52.24 per share, with a total value of $749,957.44. Following the acquisition, the director now directly owns 20,536 shares in the company, valued at approximately $1,072,801. HCA Holdings Inc (NYSE:HCA), shares advanced 0.91% in last trading session and ended the day on $52.35. HCA Holdings Inc (NYSE:HCA), return on equity ratio is recorded as -18.70% and its return on assets is 5.40%. HCA Holdings Inc (NYSE:HCA), yearly performance is 27.68%.
Opko Health (NYSE:OPK) CEO Phillip Md Et Al Frost purchased 26,000 shares of the company’s stock on the open market in a transaction dated Friday, May 2nd. The shares were purchased at an average price of $8.26 per share, for a total transaction of $214,760.00. Following the completion of the purchase, the chief executive officer now directly owns 1,987,500 shares of the company’s stock, valued at approximately $16,416,750. Opko Health Inc. (NYSE:OPK), shares moved up 1.45% in last trading session and was closed at $8.38, while trading in range of $ 8.20 – 8.47. Opko Health Inc. (NYSE:OPK), year to date (YTD) performance is -0.71%.
Omnicare, Inc. (NYSE:OCR)’s COO Nitin Sahney buy 10,000 shares of OCR in a transaction dated on April 30, 2014. Omnicare, Inc. (NYSE:OCR) shares were bought at an average price of $58.49 for total worth of $584,900.00. Omnicare, Inc. (NYSE:OCR), weekly performance is 3.05%. On last trading day company shares ended up $60.09. Omnicare, Inc. (NYSE:OCR), distance from 50-day simple moving average (SMA50) is 2.15%. Analysts mean target Price for the company is $66.67.